Quality of life of head & neck cancer patients, head & neck center, armed forces hospital Ulm
Recruiting
- Conditions
- Carcinoma of the upper aerodigestive tract including paranasal sinuses, salivary glands and CUP. Metastases localized in the head and neck area, malignant tumors of the skin in the head and neck area including metastases
- Registration Number
- DRKS00026708
- Lead Sponsor
- Bundeswehrkrankenhaus UlmKlinik und Poliklinik für HNO-Heilkunde
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Head and neck cancer
Exclusion Criteria
primary tumors of the eye and brain
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recording the quality of life of one's own patient collective to detect the parameters influencing the quality of life
- Secondary Outcome Measures
Name Time Method Recognition of parameters in the event of changes in quality of life as a marker for recurrences, second carcinoma, tumor progression, metastasis.<br>Validation and establishment of a screening tool (questionnaire) for the oncological follow-up consultation
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are associated with quality of life outcomes in head and neck squamous cell carcinoma patients in DRKS00026708?
How do EGFR or HPV status biomarkers correlate with treatment response and QoL in head and neck cancer observational studies?
What adverse events are most commonly reported in head and neck cancer patients undergoing standard-of-care therapies compared to DRKS00026708 findings?
Are PD-L1 expression or tumor mutational burden predictive of survival and QoL in head and neck cancer observational cohorts?
What combination therapies show improved QoL in metastatic head and neck cancers compared to monotherapies in recent clinical studies?